[
  {
    "path":[
      802060000,
      601260000
    ],
    "contexts":[
      " 8 Information to be included on the label (2) (f) The presentation of the critical health information, and any information mentioned in paragraphs 8(2)(c), 8(2)(d) or 8(2)(e) that is included, must be presented in black or other dark coloured texts, using only one colour, on a white or other contrasting background.",
      "6 Interpretation. \"herbal material\" means a plant or part of a plant (defined by its botanical scientific name according to the binominal nomenclature system, including author, and the plant part), whether fresh or dried, that is whole, fragmented, cut or ground;"
    ]
  },
  {
    "path":[
      601500000,
      601130000
    ],
    "contexts":[
      "6 Interpretation. \"Regulations\" means the Therapeutic Goods Regulations 1990;",
      "6 Interpretation. \"composite pack\" has the same meaning as in the Act;"
    ]
  },
  {
    "path":[
      1001000000,
      907020000
    ],
    "contexts":[
      " 10 Qualifications and special requirements (1) Preparations for ophthalmic use In addition to the requirements of sections 8 and 9 above, if a medicine is a preparation for ophthalmic use, the label on the container and on the primary pack or, where subsection 10(7) applies, the primary pack, must include: (a) the name of any antimicrobial preservative in the medicine;",
      " 9 Information to be included on the main label (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then: (b) where the medicine contains four or more active ingredients and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or"
    ]
  },
  {
    "path":[
      402000000,
      601300000
    ],
    "contexts":[
      "4 Transition arrangements (2) On and from 1 September 2020, each medicine to which this Order applies must comply with the requirements specified in this Order.",
      "6 Interpretation. \"homoeopathic preparation\" has the same meaning as in the Regulations."
    ]
  },
  {
    "path":[
      601130000,
      804060000
    ],
    "contexts":[
      "6 Interpretation. \"composite pack\" has the same meaning as in the Act;",
      " 8 Information to be included on the label (4) If the information required on the label on the container is obscured by intermediate packaging, then the label on the intermediate packaging must include: (f) the name of the sponsor or distributor, or a registered trademark if it readily identifies the sponsor or distributor of the medicine."
    ]
  },
  {
    "path":[
      1102060000,
      601430103
    ],
    "contexts":[
      " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (f) for pressurised metered dose inhalers, dry powder inhalers and other metered dose products such as nasal sprays, the quantity of the active ingredient is: (i) the quantity delivered per actuation; or where the Secretary, when registering the medicine, has accepted that the dose of products containing those active ingredients was clinically established as the metered dose, then: (ii) the quantity metered per actuation;",
      "6 Interpretation. \"name of the medicine\" means the following:(a) where the medicine is intended to be, or is, entered in the Register - the name of the medicine intended to appear or appearing on the Certificate of Registration or Certificate of Listing in relation to the medicine, not including the following information:(iii) the dosage form (except where this is integral to differentiate medicines from other medicines);"
    ]
  },
  {
    "path":[
      501170000,
      914000000
    ],
    "contexts":[
      "5 Exemptions \u2013 Medicines to which this Order does not apply  This Order does not apply to a medicine that is:(q) blood products under Item 13 that are described under paragraphs (a) and (b) under the heading \u2018HUMAN BLOOD PRODUCTS\u2019 in Appendix A to the Poisons Standard.",
      " 9 Information to be included on the main label (14) To avoid doubt, an active ingredient specified in Part 2 of Schedule 2 must be included on the main label of a medicine containing that ingredient in accordance with the Australian Approved Names List for medicine released for supply on or after 1 May 2028."
    ]
  },
  {
    "path":[
      401020010,
      401020020
    ],
    "contexts":[
      "4 Transition arrangements (1) On and from 31 August 2016 and before 1 September 2020, each medicine to which this Order applies must comply with either:(b) the requirements specified in:(i) Therapeutic Goods Order No. 69 General requirements for labels for medicines (TGO 69), up until 30 June 2017 (inclusive); or",
      "4 Transition arrangements (1) On and from 31 August 2016 and before 1 September 2020, each medicine to which this Order applies must comply with either:(b) the requirements specified in:(ii) Therapeutic Goods Order No. 69 - General Requirements for Labels for Medicines 2017 (TGO 69 (2017)), on or after 1 July 2017."
    ]
  },
  {
    "path":[
      601260000,
      601210000
    ],
    "contexts":[
      "6 Interpretation. \"herbal material\" means a plant or part of a plant (defined by its botanical scientific name according to the binominal nomenclature system, including author, and the plant part), whether fresh or dried, that is whole, fragmented, cut or ground;",
      "6 Interpretation. \"excipient\", in relation to a medicine, means an ingredient of the medicine other than the active ingredient;"
    ]
  },
  {
    "path":[
      1007080000,
      901010000
    ],
    "contexts":[
      " 10 Qualifications and special requirements (7) Small containers If: (h) the quantity of the medicine in the container; and",
      " 9 Information to be included on the main label (1) Subject to the qualifications and special requirements specified in this section and section 10 of this Order, the information on the main label of the medicine must include: (a) the name of the medicine; and"
    ]
  },
  {
    "path":[
      1009030000,
      401010000
    ],
    "contexts":[
      " 10 Qualifications and special requirements (9) Strip, blister and dial dispenser packs (c) In addition to the requirements referred to in paragraphs 10(9)(a) and (b) as relevant, if each dosage unit is enclosed in the strip or blister such that an individual segment containing the dosage unit can be readily detached, then the following information must appear on the label of the strip or blister at least once in relation to every two dosage units: (i) for a medicine to which paragraph 10(9)(a) applies \u2013 the name of the medicine, the name(s) of all active ingredients in the medicine and the quantity or proportion of all active ingredients in the medicine; and (ii) for a medicine to which paragraph 10(9)(b) applies \u2013 the name of the medicine.",
      "4 Transition arrangements (1) On and from 31 August 2016 and before 1 September 2020, each medicine to which this Order applies must comply with either:(a) the requirements specified in this Order; or"
    ]
  },
  {
    "path":[
      400000000,
      601170000
    ],
    "contexts":[
      "4 Transition arrangements (2) On and from 1 September 2020, each medicine to which this Order applies must comply with the requirements specified in this Order.",
      "6 Interpretation. \"dial dispenser pack\" means a container that has the following characteristics: (a) (b) (c) each of the dosage units is located in individual pockets preformed in a circular rigid tray; a close-fitting, rotatable, transparent lid which can only be rotated in one direction is located over the tray; and the individual dosage units can be dispensed by detaching a predefined portion of the lid or tray, and rotating the lid to the appropriate position;"
    ]
  },
  {
    "path":[
      1104000000,
      904000000
    ],
    "contexts":[
      " 11 How information is to be expressed (4) Permitted statements of storage temperature conditions For the purposes of this Order, the following statements of storage temperature conditions are permitted: (i) \u2018Store below \u201318oC (Deep freeze)\u2019; (ii) \u2018Store below \u20135oC (Freeze)\u2019; (iii) \u2018Store at 2oC to 8oC (Refrigerate. Do not freeze)\u2019; (iv) \u2018Store below 25oC\u2019; (v) \u2018Store below 30oC\u2019; (vi) for a medicine that is, or is intended to be, registered goods, any other storage temperature conditions as specified in the approved product details in relation to the medicine.",
      " 9 Information to be included on the main label (4) All text required by this Order to be on the main label must be oriented in the same direction."
    ]
  },
  {
    "path":[
      601290000,
      601140000
    ],
    "contexts":[
      "6 Interpretation. \"homoeopathic potency\" means the dilution factor of a homoeopathic preparation, expressed as: (a) (b) \\\"nX\\\" where each dilution is a decimal or ten-fold dilution and \\\"n\\\" is the number of dilutions such that the total dilution is 10n; or \\\"nC\\\" where each dilution is a centesimal or hundred-fold dilution and \\\"n\\\" is the number of dilutions such that the total dilution is 100n; or (c) \\\"nLM\\\" or \\\"LMn\\\" where, from a 3C starting dilution, each subsequent dilution is a fifty millesimal or fifty thousand fold dilution and \\\"n\\\" is the number of dilutions such that the total dilution is 50,000^n. Note: Where 1000 centesimal dilutions are performed, the potency is expressed as nM; that is, 1M potency represents a 1,000C dilution, 2M a 2,000C dilution, etc",
      "6 Interpretation. \"container\" has the same meaning as in the Act;"
    ]
  },
  {
    "path":[
      903020000,
      601440000
    ],
    "contexts":[
      " 9 Information to be included on the main label (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must: (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;",
      "6 Interpretation. \"Poisons Standard\" means the current Poisons Standard as defined in section 52A of the Act;"
    ]
  },
  {
    "path":[
      1006070000,
      914000000
    ],
    "contexts":[
      " 10 Qualifications and special requirements (6) Medicine kits The label on a package that, together with medicines, constitutes a medicine kit must include the following information: (g) an expiry date for the kit, being the earliest expiry date of the medicines within the kit, preceded by the expiry date prefix;",
      " 9 Information to be included on the main label (14) To avoid doubt, an active ingredient specified in Part 2 of Schedule 2 must be included on the main label of a medicine containing that ingredient in accordance with the Australian Approved Names List for medicine released for supply on or after 1 May 2028."
    ]
  },
  {
    "path":[
      905030000,
      601490000
    ],
    "contexts":[
      " 9 Information to be included on the main label (5) If the medicine contains: (c) if the medicine is intended to be, or is, registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.",
      "6 Interpretation. \"registration number\" means the combination of numbers and letters that is required to be included on the label of medicines in a manner described in regulation 15 of the Regulations;"
    ]
  },
  {
    "path":[
      601100000,
      1102020000
    ],
    "contexts":[
      "6 Interpretation. \"Certificate of Listing\", in relation to a medicine, means the certificate given to the applicant for listing of the medicine under subsection 26(4) or subsection 26A(9) of the Act in relation to that medicine;",
      " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (b) for a solid for ingestion, where there is no discrete dosage unit - as the quantity of the active ingredient contained in the stated weight of a suitable dose of the solid;"
    ]
  },
  {
    "path":[
      601450000,
      601100000
    ],
    "contexts":[
      "6 Interpretation. \"primary pack\" has the same meaning as in the Act;",
      "6 Interpretation. \"Certificate of Listing\", in relation to a medicine, means the certificate given to the applicant for listing of the medicine under subsection 26(4) or subsection 26A(9) of the Act in relation to that medicine;"
    ]
  },
  {
    "path":[
      501000000,
      903000000
    ],
    "contexts":[
      "5 Exemptions \u2013 Medicines to which this Order does not apply  This Order does not apply to a medicine that is:(i) imported for use in the treatment of the importer or the importer\u2019s immediate family as set out in Item 1 of Schedule 5 to the Regulations; or",
      " 9 Information to be included on the main label (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must: (a) appear as a cohesive unit by the placing of the name and quantity of each active ingredient together on separate lines of text either (i) immediately below the name of the medicine; or (ii) where the trademark of the medicine might be disrupted or obscured, adjacent to the name of the medicine; and"
    ]
  },
  {
    "path":[
      601120000,
      801060000
    ],
    "contexts":[
      "6 Interpretation. \"complementary healthcare practitioner\" means a person described in paragraph 42AA(1)(c) of the Act;",
      " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (f) the batch number of the medicine preceded by the batch number prefix; and"
    ]
  },
  {
    "path":[
      601160000,
      101000002
    ],
    "contexts":[
      "6 Interpretation. \"delivered dose\" means, in relation to: (a) metered dose preparations - the dose delivered to the patient in a single actuation or delivery; and (b) powders for inhalation - the dose delivered from the inhaler in a single delivery;",
      "Introduction (2) The purpose of the label on a medicine is to provide information about the medicine such as its identity, potency, content, storage, expiry date, dose, directions for use, sponsor details and registration\/listing status. Labels on medicines can also include other information not required by this Order but which may be required by other legislation or for commercial purposes such as the sponsor\u2019s logo."
    ]
  },
  {
    "path":[
      601570000,
      101000001
    ],
    "contexts":[
      "6 Interpretation. \"stated volume of fill\" means the volume of medicine that the container is specified by the sponsor to contain;",
      "Introduction (1) This Order sets out what kinds of information are required to be included on the label of medicines of the kind described in section 3, and in what circumstances."
    ]
  },
  {
    "path":[
      802050000,
      908000000
    ],
    "contexts":[
      " 8 Information to be included on the label (2) (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details.",
      " 9 Information to be included on the main label (8) Where a medicine is: (d) the information required under either paragraph 9(6)(b) or subsection 9(7) must be provided separately in relation to each formulation of medicine in the composite pack or medicine kit."
    ]
  },
  {
    "path":[
      1007120000,
      804020000
    ],
    "contexts":[
      " 10 Qualifications and special requirements (7) Small containers If: (l) if the medicine is contained in an ampoule - a statement of the approved route of administration for the medicine, such as \u2018inhalation\u2019, \u2018For oral use only\u2019 or other phrase, word or abbreviation denoting the approved route(s) of administration of the medicine; and",
      " 8 Information to be included on the label (4) If the information required on the label on the container is obscured by intermediate packaging, then the label on the intermediate packaging must include: (b) the name(s) of all active ingredients in the medicine; and"
    ]
  },
  {
    "path":[
      401020010,
      101000006
    ],
    "contexts":[
      "4 Transition arrangements (1) On and from 31 August 2016 and before 1 September 2020, each medicine to which this Order applies must comply with either:(b) the requirements specified in:(i) Therapeutic Goods Order No. 69 General requirements for labels for medicines (TGO 69), up until 30 June 2017 (inclusive); or",
      "Introduction (6) Guidelines to assist in the design of medicine labels are available on the Therapeutic Goods Administration website (http:\/\/www.tga.gov.au)."
    ]
  },
  {
    "path":[
      1008030000,
      601410000
    ],
    "contexts":[
      " 10 Qualifications and special requirements (8) Individually wrapped medicines (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.",
      "6 Interpretation. \"name of an excipient\" means the name of the excipient that is accepted for inclusion in the Australian Approved Names List;"
    ]
  },
  {
    "path":[
      601270000,
      1102000000
    ],
    "contexts":[
      "6 Interpretation. \"herbal preparation\" means an ingredient that is the result of the processing of a herbal material;",
      " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (e) for a transdermal patch, as the total quantity of the active ingredient in each patch and the quantity of the active ingredient released in a stated time;"
    ]
  },
  {
    "path":[
      1006080000,
      100000000
    ],
    "contexts":[
      " 10 Qualifications and special requirements (6) Medicine kits The label on a package that, together with medicines, constitutes a medicine kit must include the following information: (h) any warning statements that relate to any of the medicines within the kit;",
      "About this compilation Uncommenced amendments The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law."
    ]
  },
  {
    "path":[
      910000000,
      101000006
    ],
    "contexts":[
      " 9 Information to be included on the main label (10) Subsection 9(9) does not apply: (b) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2\u2014after 30 April 2026; or",
      "Introduction (6) Guidelines to assist in the design of medicine labels are available on the Therapeutic Goods Administration website (http:\/\/www.tga.gov.au)."
    ]
  },
  {
    "path":[
      1100000000,
      702000000
    ],
    "contexts":[
      " 11 How information is to be expressed (4) Permitted statements of storage temperature conditions For the purposes of this Order, the following statements of storage temperature conditions are permitted: (i) \u2018Store below \u201318oC (Deep freeze)\u2019; (ii) \u2018Store below \u20135oC (Freeze)\u2019; (iii) \u2018Store at 2oC to 8oC (Refrigerate. Do not freeze)\u2019; (iv) \u2018Store below 25oC\u2019; (v) \u2018Store below 30oC\u2019; (vi) for a medicine that is, or is intended to be, registered goods, any other storage temperature conditions as specified in the approved product details in relation to the medicine.",
      " 7 General requirements, including label presentation (2) The information required by this Order to be included on a label or labels must: (b) be in English; and"
    ]
  },
  {
    "path":[
      101000000,
      601070000
    ],
    "contexts":[
      "Introduction (3) The information included on a label contributes to the quality use of medicines. Quality use of medicines means selecting management options wisely, choosing suitable medicines if a medicine is considered necessary, and using those medicines safely and effectively.",
      "6 Interpretation. \"batch number prefix\" means the prefix which precedes the batch number and has the following characteristics: (a) clearly indicates that the information following the prefix is the batch number; and (b) is in the following form: \\\"BATCH NUMBER\\\", \\\"BATCH NO.\\\", \\\"BATCH\\\", \\\"B\\\", \\\"(B)\\\", \\\"B\/N\\\", \\\"LOT NUMBER\\\", \\\"LOT NO.\\\", or \\\"LOT\\\", or words or symbols to this effect, including a mixture of lower and upper case letters;"
    ]
  },
  {
    "path":[
      601430105,
      501130000
    ],
    "contexts":[
      "6 Interpretation. \"name of the medicine\" means the following:(a) where the medicine is intended to be, or is, entered in the Register - the name of the medicine intended to appear or appearing on the Certificate of Registration or Certificate of Listing in relation to the medicine, not including the following information:(v) the pack size;",
      "5 Exemptions \u2013 Medicines to which this Order does not apply  This Order does not apply to a medicine that is:(m) made up or compounded extemporaneously, for a specific and individual case, by a complementary healthcare practitioner in the lawful practice of his or her profession; or"
    ]
  },
  {
    "path":[
      1007070000,
      1005010000
    ],
    "contexts":[
      " 10 Qualifications and special requirements (7) Small containers If: (g) the name of the dosage form; and",
      " 10 Qualifications and special requirements (5) Sunscreen preparations If: (a) the medicine is a sunscreen preparation; and"
    ]
  },
  {
    "path":[
      801150000,
      1103000000
    ],
    "contexts":[
      " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (o) if the medicine is contained in an ampoule, a statement of the approved route of administration for the medicine, such as \u2018inhalation\u2019, \u2018For oral use only\u2019 or other phrase, word or abbreviation denoting the approved route(s) of administration.",
      " 11 How information is to be expressed (3) Expression of quantity or proportion of active ingredients for homoeopathic preparations The label on the container and on the primary pack of a medicine that contains a homoeopathic preparation must include: (c) where paragraphs (a) and (b) do not apply- the quantity of the preparation in one millilitre or in one gram of the medicine"
    ]
  },
  {
    "path":[
      1102100000,
      1007120000
    ],
    "contexts":[
      " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (j) for any other medicines: (i) where the medicine is a liquid and includes an active ingredient which is a liquid - as the appropriate amount of the active ingredient, either by weight or volume, in a stated volume of the medicine; (ii) where the medicine is a liquid and includes an active ingredient which is a solid - as the weight of active ingredient in a stated volume of the medicine; (iii) where the medicine is a liquid and includes an active ingredient which is a gas - as the weight of the active ingredient in a stated volume of the medicine; (iv) where the medicine is a solid or semi-solid and includes an active ingredient which is a liquid - as the appropriate amount of the active ingredient, either by weight or volume, in a stated weight of the medicine; (v) where the medicine is a solid or semi-solid and includes an active ingredient which is a solid - as the weight of the active ingredient in a stated weight of the medicine.",
      " 10 Qualifications and special requirements (7) Small containers If: (l) if the medicine is contained in an ampoule - a statement of the approved route of administration for the medicine, such as \u2018inhalation\u2019, \u2018For oral use only\u2019 or other phrase, word or abbreviation denoting the approved route(s) of administration of the medicine; and"
    ]
  },
  {
    "path":[
      501150000,
      601460002
    ],
    "contexts":[
      "5 Exemptions \u2013 Medicines to which this Order does not apply  This Order does not apply to a medicine that is:(o) a medical gas; or",
      "6 Interpretation. \"quantity of the medicine\" means: (a) where the medicine consists of discrete dosage units, such as tablets or capsules or sachets \u2013 the stated number of units in the container; or(b) where the medicine is: (i) a solid or semi-solid - the stated weight in the container; (ii) a liquid - the stated volume of fill in the container; (iii) a pressurised metered-dose preparation or dry powder inhaler - the stated number of deliverable doses in the container; (iv) a non-pressurised metered dose preparation - the minimum number of deliverable doses in the container;"
    ]
  },
  {
    "path":[
      1006070000,
      908040000
    ],
    "contexts":[
      " 10 Qualifications and special requirements (6) Medicine kits The label on a package that, together with medicines, constitutes a medicine kit must include the following information: (g) an expiry date for the kit, being the earliest expiry date of the medicines within the kit, preceded by the expiry date prefix;",
      " 9 Information to be included on the main label (8) Where a medicine is: (d) the information required under either paragraph 9(6)(b) or subsection 9(7) must be provided separately in relation to each formulation of medicine in the composite pack or medicine kit."
    ]
  },
  {
    "path":[
      905010000,
      901020000
    ],
    "contexts":[
      " 9 Information to be included on the main label (5) If the medicine contains: (a) two or more active ingredients; and",
      " 9 Information to be included on the main label (1) Subject to the qualifications and special requirements specified in this section and section 10 of this Order, the information on the main label of the medicine must include: (b) the name(s) of all active ingredients in the medicine; and"
    ]
  },
  {
    "path":[
      1007030000,
      901050000
    ],
    "contexts":[
      " 10 Qualifications and special requirements (7) Small containers If: (c) the name of the medicine; and",
      " 9 Information to be included on the main label (1) Subject to the qualifications and special requirements specified in this section and section 10 of this Order, the information on the main label of the medicine must include: (e) the quantity of the medicine; and"
    ]
  },
  {
    "path":[
      300000000,
      601460003
    ],
    "contexts":[
      "3 Application - Therapeutic goods to which this Order applies(2) To avoid doubt, this Order will apply to the following medicines:(a) medicines of a kind specified in Parts 2 and 3 of Schedule 10 to the Regulations and",
      "6 Interpretation. \"quantity of the medicine\" means: (a) where the medicine consists of discrete dosage units, such as tablets or capsules or sachets \u2013 the stated number of units in the container; or(c) where the medicine is a medicine of any of the kinds referred to in paragraph (b) and the medicine consists of a number of identical containers within the primary pack \u2013 the number of containers (e.g. 5 x 10 mL vials);"
    ]
  },
  {
    "path":[
      601150000,
      601330000
    ],
    "contexts":[
      "6 Interpretation. \"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer;",
      "6 Interpretation. \"listed goods\" has the same meaning as in the Act;"
    ]
  },
  {
    "path":[
      804040000,
      1010010000
    ],
    "contexts":[
      " 8 Information to be included on the label (4) If the information required on the label on the container is obscured by intermediate packaging, then the label on the intermediate packaging must include: (d) the batch number of the medicine preceded by the batch number prefix; and",
      " 10 Qualifications and special requirements (10) Plastic ampoules (a) Subject to paragraph (b), if: (i) a medicine is contained in a plastic ampoule; and (ii) the capacity of the container of the medicine in the plastic ampoule is 8 millilitres or less; and (iii) two or more ampoules are attached to a connecting strip; and (iv) the ampoules and their connecting strip are enclosed in a primary pack that complies with the requirements of this Order, then the information required by this Order to appear on the label of the container of the medicine may be divided between the ampoule and the connecting strip."
    ]
  },
  {
    "path":[
      601460002,
      802030000
    ],
    "contexts":[
      "6 Interpretation. \"quantity of the medicine\" means: (a) where the medicine consists of discrete dosage units, such as tablets or capsules or sachets \u2013 the stated number of units in the container; or(b) where the medicine is: (i) a solid or semi-solid - the stated weight in the container; (ii) a liquid - the stated volume of fill in the container; (iii) a pressurised metered-dose preparation or dry powder inhaler - the stated number of deliverable doses in the container; (iv) a non-pressurised metered dose preparation - the minimum number of deliverable doses in the container;",
      " 8 Information to be included on the label (2) (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order."
    ]
  },
  {
    "path":[
      601410000,
      601270000
    ],
    "contexts":[
      "6 Interpretation. \"name of an excipient\" means the name of the excipient that is accepted for inclusion in the Australian Approved Names List;",
      "6 Interpretation. \"herbal preparation\" means an ingredient that is the result of the processing of a herbal material;"
    ]
  },
  {
    "path":[
      1105010000,
      801130000
    ],
    "contexts":[
      " 11 How information is to be expressed (5) Inclusion of common names of vitamins Where a medicine contains an active ingredient that is a vitamin, then the word \u2018vitamin\u2019, or any suitable unambiguous abbreviation of the word vitamin, together with the common name of that vitamin, may appear on a main label of the medicine either: (a) on the same line of text - between the approved name of the active ingredient that is a vitamin and the quantity of that active ingredient; or",
      " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (m) if the medicine requires some preparation, such as dissolving, suspending, diluting or reconstituting before use - instructions for its preparation and, where relevant, a statement of the conditions of storage and the maximum period of storage between preparation and use, except where: (i) there is insufficient space on the label of either the container or the primary pack, or both, to include this information; and (ii) this information is set out in a package insert provided in the primary pack of the medicine; and (iii) a statement is included on whichever label on the container or the primary pack, or both, that does not set out the information itself, that this information is set out in the package insert; and"
    ]
  },
  {
    "path":[
      905020000,
      802010000
    ],
    "contexts":[
      " 9 Information to be included on the main label (5) If the medicine contains: (b) at least two of those active ingredients belong to any of the following categories: (i) a vitamin that is identified by both: (A) the approved name of the active ingredient that is a vitamin; and (B) in accordance with subsection 11(5), the word \u2018vitamin\u2019, or any suitable unambiguous abbreviation of the word vitamin, together with the common name of that vitamin; or (ii) a mineral;  (iii) a herbal preparation that, under subparagraph 11(2)(i)(ii), is required to be quantified as either: (A) the dry or fresh weight of herbal material from which the preparation was derived; or (B) the minimum dry or fresh weight of herbal material from which the preparation was derived, then: the names, and quantities or proportions, of all active ingredients in the medicine may appear on a side panel or side label or on a rear panel or rear label instead of on the main label; and",
      " 8 Information to be included on the label (2) (a) Subject to paragraphs (b), (c) and (d), where the medicine is registered goods, the critical health information must be displayed on the label of the primary pack in a tabulated form."
    ]
  },
  {
    "path":[
      1006030000,
      601570000
    ],
    "contexts":[
      " 10 Qualifications and special requirements (6) Medicine kits The label on a package that, together with medicines, constitutes a medicine kit must include the following information: (c) the name of each of the medicines within the kit and its dosage form;",
      "6 Interpretation. \"stated volume of fill\" means the volume of medicine that the container is specified by the sponsor to contain;"
    ]
  },
  {
    "path":[
      1105020000,
      801070000
    ],
    "contexts":[
      " 11 How information is to be expressed (5) Inclusion of common names of vitamins Where a medicine contains an active ingredient that is a vitamin, then the word \u2018vitamin\u2019, or any suitable unambiguous abbreviation of the word vitamin, together with the common name of that vitamin, may appear on a main label of the medicine either: (b) on a separate line of text - immediately below the related name of the active ingredient that is a vitamin and the quantity of that active ingredient.",
      " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (g) the expiry date of the medicine, preceded by the expiry date prefix; and"
    ]
  },
  {
    "path":[
      903030000,
      101000000
    ],
    "contexts":[
      " 9 Information to be included on the main label (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must: (c) if the medicine is: (i) supplied in either a small or a medium container; and (ii) contains multiple active ingredients then, in relation to compliance of the label with paragraph 9(3)(a), the names of the multiple active ingredients and their quantities may be presented together on a continuous line, or lines, of text.",
      "Introduction (5) This Order also sets out general requirements for the labels of non- prescription medicines. The purpose of the Order is to facilitate the quality use of those medicines by consumers and health professionals by ensuring appropriate labelling. Consideration of the following objectives in designing labels, and assessing and determining compliance with the requirements of this Order, will assist in achieving that purpose: - minimising the risk of prescribing, dispensing and self-selection errors; - enhancing consumer safety; - avoiding consumer confusion and the inappropriate use of medicines (including misuse, over-use, and under-use); - assisting the appropriate selection of those medicines; - assisting the safe and effective use of those medicines; - optimising identification and usability of necessary information; - improving consumers\u2019 ability to solve problems related to those medicines, such as managing multiple medicines; and - where relevant, ensuring consumers are aware of where to go for further information about their medicine."
    ]
  }
]